Pulmatrix Phase 1 data for inhaled DHE (PUR3100) published: rapid absorption, better tolerability vs IV DHE

Pulmatrix, Inc.

All PUR3100 doses showed mean Cmax above 1000 pg/mL efficacy threshold; Tmax 5 min vs 5.5 min for IV DHE.
Lower incidence of nausea (21% vs 86%), vomiting (0% vs 29%), and headache (16% vs 57%) compared to IV DHE.
Data published in Headache: The Journal of Head and Face Pain; FDA allowed Phase 2 study to proceed.
Company seeking financing or partnership to advance PUR3100 into Phase 2 for acute migraine.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.